Its mechanism of action is primarily via PARP inhibition but also acts via sensitising cancer cells to DNA-damaging drugs, such as oxaliplatin, cisplatin, carboplatin, irinotecan, and cyclophosphamide, as well as radiotherapy [48]. This evidence concerns the gene PARP1 and cancer.